Camber FDA Wednesday, March 22, 2017 0.00 Neutral

FDA Approves OXYCODONE AND ACETAMINOPHEN — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals gained FDA approval for its ANDA207419 formulation of oxycodone and acetaminophen tablets, granting the company the rights to supply a lower-cost alternative to the branded drug. This approval is poised to impact the market by intensifying competitive pricing and eroding the market share of the incumbent brand sponsor.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day